Market World Carcinoembryonic Antigen Market | Página 2

Favorable government initiatives to introduce new diagnostic tools/technologies is anticipated to boost the
market growth. Moreover, rising demand for minimally invasive diagnostic procedures to avoid the various post
procedure adverse effects impel the growth of this market.
Application Insights
This segment include key application, namely colorectal, ovarian, pancreatic, breast, thyroid and other cancer
applications. In 2016, colorectal cancer dominated the market in terms of revenue share. Rising incidence of
colorectal cancer and increase sensitivity to detect the antigen are the factors driving the growth of this
segment. According to the American Cancer Society, in the U.S colorectal cancer is the third leading cause of
death in women and second in men with nearly 95,520 new cases of colon cancer. Furthermore, increased
consumption of alcohol, less physical activity, unhealthy diet, and rapidly changing lifestyle also contribute in
the growth of colorectal cancer in the recent years.
Breast cancer is another segment experiencing significant growth owing to the factors such as rising female
population above 50 years, advancements in biomarkers and increase in number of patients undertaking
hormone replacement therapy (HRT), and breast augmentation & reconstruction surgery. Increasing
government initiative coupled with rising consumer awareness for different treatment procedures is also driving
the growth of the market. Moreover, other breast related diseases such as infections, lesions, and fibrocysts are
also expected to contribute towards the growth in early diagnosis.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/carcinoembryonic-antigen-cea-market
Regional Insight
Regional segments of CEA market include North America, Europe, Asia Pacific, Latin America and MEA. In 2016,
North America dominate the regional market pertaining to various key attributes such as increasing patient
awareness, rising incidences of cancer, favorable reimbursement policies, and presence of advanced healthcare
infrastructure. According to American Cancer Society in 2017, approximately 1,688,780 new cases of cancer
were estimated in the U.S.
Asia Pacific region is expected to grow at lucrative rates during the forecast period owing to the factors such as
increasing prevalence of cancer in emerging economies such as Brazil, Russia, India, and China, favorable
government initiatives, and significant presence of local players will drive the growth of the market in this region.
Asia Pacific has the highest mortality rate accompanied by North America. It has influenced the market in terms
of cancer incidence rate affecting large population in 2012 at a changeable rate. Mexico and Brazil in Latin